Five-year follow-up of a cohort of profoundly immunosuppressed patients discontinuing therapy for cytomegalovirus retinitis.
Potent antiretroviral therapy stimulates robust and durable immune reconstitution among profoundly immunosuppressed patients that is clinically important. Fifteen patients with cytomegalovirus retinitis (CMVR) were followed after discontinuing anti-cytomegalovirus therapy. No patients had progression or relapse for a median of 51 months. Survival from the diagnosis of CMVR was universal for up to 95 months, with an observation period averaging more than 6 years. The CD4 cell count continued to rise through the fourth year of follow-up.
Sklar
Peter A
PA
The Critical Care Medicine Department, Clinical Center, National Institute of Allergy and Infectious Diseases, National Eye Institute, National Institutes of Health, Bethesda, MD, USA.
Agyemang
Amma F
AF
Monastra
Rachelle
R
Kress
Diane Rock
DR
Metcalf
Julia A
JA
Robinson
Michael R
MR
Masur
Henry
H
Polis
Michael A
MA
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy / Q000276:immunology*; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D017726:Cytomegalovirus Retinitis / Q000188:drug therapy / Q000276:immunology*; D005500:Follow-Up Studies; D006801:Humans; D007108:Immune Tolerance